Breast Cancer: SWOG S1105 (Iowa Cancer Specialists)

SWOG S1105: Randomized Trial of Text-Messaging Intervention to Reduce Early Discontinuation of Adjuvant Aromatase Inhibitor Therapy in Women with Early Stage Breast Cancer.

Objective

This study is being done because many women who are on oral aromatase inhibitor (AI) therapy for a long period of time don’t take it regularly. The purpose of this study is to find out the reasons why women don’t take it regularly and also to see if text messaging will help women remember to take their AI medication and stay on the treatment.

Individuals eligible for this study are those with a diagnosis of Stage I-III breast cancer that have finished chemotherapy and surgery, as needed, and are currently being treated with an aromatase inhibitor.

Principal Investigator(s)
George Kovach

Clinical Trial Categories

  • Cancer
  • Breast Cancer
Sponsor(s)
SWOG
Contact
Kim Turner, R.N. at 563-421-1908
or turnerk@genesishealth.com

Location

  • Cancer Care Institute
    1351 West Central Park
    Pavilion 1, 1st Floor
    Davenport, IA 52804
    Main: 563-421-1900
    Alternate: 800-446-6088
    Fax: 563-421-1938

Contact Us

For more information about our research program and IRB, please contact:

Research Support Office
563-421-7955

Email